Antifungal Agents for the Treatment of Systemic Fungal Infections in Children

Traditionally, the mainstay of systemic antifungal therapy has been amphotericin B deoxycholate (conventional amphotericin B). Newer agents have been developed to fulfill special niches and to compete with conventional amphotericin B by virtue of having more favourable toxicity profiles. Some agents...

Full description

Saved in:
Bibliographic Details
Main Author: UD Allen
Format: Article
Language:English
Published: Wiley 2010-01-01
Series:Canadian Journal of Infectious Diseases and Medical Microbiology
Online Access:http://dx.doi.org/10.1155/2010/784549
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849396466982846464
author UD Allen
author_facet UD Allen
author_sort UD Allen
collection DOAJ
description Traditionally, the mainstay of systemic antifungal therapy has been amphotericin B deoxycholate (conventional amphotericin B). Newer agents have been developed to fulfill special niches and to compete with conventional amphotericin B by virtue of having more favourable toxicity profiles. Some agents have displaced conventional amphotericin B for the treatment of specific fungal diseases. For example, voriconazole has emerged as the preferred treatment for invasive pulmonary aspergillosis. This notwithstanding, conventional amphotericin B remains a useful agent for the treatment of paediatric fungal infections. Knowledge of the characteristics of the newer agents is important, given the increasing numbers of patients who are being treated with these drugs. Efforts need to be directed at research aimed at generating paediatric data where these are lacking. The antifungal agents herein described are most often used as monotherapy regimens because there is no uniform consensus on the value of combination therapy, except for specific scenarios.
format Article
id doaj-art-b34e3fe34a414520b7124607e94ff4c8
institution Kabale University
issn 1712-9532
language English
publishDate 2010-01-01
publisher Wiley
record_format Article
series Canadian Journal of Infectious Diseases and Medical Microbiology
spelling doaj-art-b34e3fe34a414520b7124607e94ff4c82025-08-20T03:39:19ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95322010-01-01214e116e12110.1155/2010/784549Antifungal Agents for the Treatment of Systemic Fungal Infections in ChildrenUD AllenTraditionally, the mainstay of systemic antifungal therapy has been amphotericin B deoxycholate (conventional amphotericin B). Newer agents have been developed to fulfill special niches and to compete with conventional amphotericin B by virtue of having more favourable toxicity profiles. Some agents have displaced conventional amphotericin B for the treatment of specific fungal diseases. For example, voriconazole has emerged as the preferred treatment for invasive pulmonary aspergillosis. This notwithstanding, conventional amphotericin B remains a useful agent for the treatment of paediatric fungal infections. Knowledge of the characteristics of the newer agents is important, given the increasing numbers of patients who are being treated with these drugs. Efforts need to be directed at research aimed at generating paediatric data where these are lacking. The antifungal agents herein described are most often used as monotherapy regimens because there is no uniform consensus on the value of combination therapy, except for specific scenarios.http://dx.doi.org/10.1155/2010/784549
spellingShingle UD Allen
Antifungal Agents for the Treatment of Systemic Fungal Infections in Children
Canadian Journal of Infectious Diseases and Medical Microbiology
title Antifungal Agents for the Treatment of Systemic Fungal Infections in Children
title_full Antifungal Agents for the Treatment of Systemic Fungal Infections in Children
title_fullStr Antifungal Agents for the Treatment of Systemic Fungal Infections in Children
title_full_unstemmed Antifungal Agents for the Treatment of Systemic Fungal Infections in Children
title_short Antifungal Agents for the Treatment of Systemic Fungal Infections in Children
title_sort antifungal agents for the treatment of systemic fungal infections in children
url http://dx.doi.org/10.1155/2010/784549
work_keys_str_mv AT udallen antifungalagentsforthetreatmentofsystemicfungalinfectionsinchildren